Dean Petkanas

Company: Neuropathix

Job title: Chief Executive Officer

Seminars:

Panel Discussion: Overcoming Challenges for Pharmaceutical Engagement in R&D for Cannabinoid & Endocannabinoid System Targeting Drug Development 3:30 pm

How can pharma work with other stakeholders to de-risk investment in cannabinoid drug development? What actions can be taken to de-stigmatise cannabinoid drug development across large pharma? How have the first few breakthrough regulatory approvals paved the way for more widely accepted cannabinoid drug development within pharma? How can emerging technologies and innovative approaches within…Read more

day: Conference Day 1

Novel First-In-Class NCE Targeting GPR55, a Pro-Inflammatory Orphan Cannabinoid Receptor 9:30 am

Assessing GPR55 as a target for reducing neuroinflammation and neuropathic pain in preclinical studies Advancing a GPR55-targeting drug in preclinical development to address chemotherapy-induced peripheral neuropathy, mitigating pain without interfering with cancer treatment, crucial for maintaining patient compliance with chemotherapy regimens Demonstrating the significant impact of this novel compound on mitochondrial health and GPR55 signalling,…Read more

day: Day Two

Panel Discussion: Overcoming Challenges for Pharmaceutical Engagement in R&D for Cannabinoid & Endocannabinoid System Targeting Drug Development 3:30 pm

How can pharma work with other stakeholders to de-risk investment in cannabinoid drug development? What actions can be taken to de-stigmatise cannabinoid drug development across large pharma? How have the first few breakthrough regulatory approvals paved the way for more widely accepted cannabinoid drug development within pharma? How can emerging technologies and innovative approaches within…Read more

day: Day One PM